ConductScience.org, home

Comparison · NCT02028676-562829d9

Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Continued Cotrimoxazole Prophylaxis vs Stopped Cotrimoxazole Prophylaxis: Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea. Trial comparisons, record NCT02028676-562829d9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02028676-562829d9

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.002660.000470.0149wilson
Risk in group 20.01050.004080.0266wilson
Risk difference, group 1 minus group 2-0.00781-0.02410.00601newcombe hybrid score
Risk ratio, group 1 over group 20.2540.02852.26log
Odds ratio, group 1 over group 20.2520.0282.27log
Number needed to treat, for one fewer participant with the outcome on Continued Cotrimoxazole Prophylaxis than on Stopped Cotrimoxazole Prophylaxis128from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Continued Cotrimoxazole ProphylaxisOther Names:~trimethoprim+sulfamethoxazole1376OG000
Group 2Stopped Cotrimoxazole Prophylaxis4382OG001

Outcome

Type
SECONDARY
Title
Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea
Description
Number of participants with a new WHO stage 3 severe recurrent pneumonia or diarrhoea, to be analysed using time-to-event methods
Time frame
Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)
Population

Source ClinicalTrials.gov

Trial

Title
Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
NCT number
NCT02028676
Phases
PHASE4
Conditions
Human Immunodeficiency Virus
Interventions
Clinically Driven Monitoring (CDM), Laboratory plus Clinical Monitoring (LCM), Arm A: ABC+3TC+NNRTI, Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance, Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance, Once-daily ABC+3TC, Twice-daily ABC+3TC, Continued cotrimoxazole prophylaxis, Stopped cotrimoxazole prophylaxis
Lead sponsor
Medical Research Council
Results first posted
2014-06-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02028676-562829d9